Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.46 |
| ▸ | PDE4A | P27815 | 4/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701421 | 0.92 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4284416 | 0.88 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4271328 | 0.88 | PTGS2 (0.45) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4279613 | 0.87 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4285870 | 0.86 | PDE4A (0.43) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4285834 | 0.86 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4271738 | 0.86 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL20053165 | 0.86 | PDE4A (0.44) | PDE4BPDE4APDE4CPDE4DFPR2 | |
| SCHEMBL4275018 | 0.86 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4DHPGD | |
| SCHEMBL4278862 | 0.86 | PDE4A (0.44) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637559-B2 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4B 5/4885PDE4A 2/4885PDE4C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.